KR20220098168A - 간 장애의 치료 - Google Patents

간 장애의 치료 Download PDF

Info

Publication number
KR20220098168A
KR20220098168A KR1020227018657A KR20227018657A KR20220098168A KR 20220098168 A KR20220098168 A KR 20220098168A KR 1020227018657 A KR1020227018657 A KR 1020227018657A KR 20227018657 A KR20227018657 A KR 20227018657A KR 20220098168 A KR20220098168 A KR 20220098168A
Authority
KR
South Korea
Prior art keywords
compound
patient
liver
formula
pharmaceutically acceptable
Prior art date
Application number
KR1020227018657A
Other languages
English (en)
Korean (ko)
Inventor
마르티즌 페노
유진 왕
웨이동 종
케빈 클루처
Original Assignee
테른스 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테른스 파마슈티칼스, 인크. filed Critical 테른스 파마슈티칼스, 인크.
Publication of KR20220098168A publication Critical patent/KR20220098168A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227018657A 2019-11-08 2020-11-06 간 장애의 치료 KR20220098168A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US62/933,277 2019-11-08
US202063004403P 2020-04-02 2020-04-02
US63/004,403 2020-04-02
PCT/US2020/059522 WO2021092474A1 (fr) 2019-11-08 2020-11-06 Traitement de troubles hépatiques

Publications (1)

Publication Number Publication Date
KR20220098168A true KR20220098168A (ko) 2022-07-11

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018657A KR20220098168A (ko) 2019-11-08 2020-11-06 간 장애의 치료

Country Status (11)

Country Link
EP (1) EP4054567A4 (fr)
JP (1) JP2023501386A (fr)
KR (1) KR20220098168A (fr)
CN (1) CN114667142A (fr)
AU (1) AU2020380968A1 (fr)
BR (1) BR112022008639A2 (fr)
CA (1) CA3160445A1 (fr)
CL (1) CL2022001167A1 (fr)
IL (1) IL292459A (fr)
MX (1) MX2022005407A (fr)
WO (1) WO2021092474A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021400488A1 (en) 2020-12-14 2023-06-22 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
AU2017241559A1 (en) * 2016-03-28 2018-11-01 Intercept Pharmaceuticals, Inc. Medicine obtained by combining FXR agonist and ARB
US20200131129A1 (en) * 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2019023245A1 (fr) * 2017-07-25 2019-01-31 Cedars-Sinai Medical Center Méthodes de traitement de maladies hépatiques
JP2022508402A (ja) * 2018-08-30 2022-01-19 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の治療

Also Published As

Publication number Publication date
EP4054567A4 (fr) 2024-01-10
MX2022005407A (es) 2022-05-24
AU2020380968A1 (en) 2022-05-12
WO2021092474A1 (fr) 2021-05-14
CA3160445A1 (fr) 2021-05-14
CL2022001167A1 (es) 2023-02-10
IL292459A (en) 2022-06-01
JP2023501386A (ja) 2023-01-18
CN114667142A (zh) 2022-06-24
BR112022008639A2 (pt) 2022-07-19
EP4054567A1 (fr) 2022-09-14

Similar Documents

Publication Publication Date Title
US20240000765A1 (en) Combination treatment of liver disorders
US20210379040A1 (en) Combination treatment of liver disorders
Davis Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics
US20210121418A1 (en) Treatment of proteinuria
KR20220098168A (ko) 간 장애의 치료
US20220387414A1 (en) Treating liver disorders
US20230241071A1 (en) Combination treatment of liver disorders
KR101057485B1 (ko) 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
EP4166137A1 (fr) Agent thérapeutique pour la stéatose hépatique non alcoolique
KR20220054593A (ko) 병용 치료를 위한 화합물
Haddley Lu-AA-21004